Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia

被引：0
|
作者：
Enriqueta Albizua
Miguel Gallardo
Santiago Barrio
Inmaculada Rapado
Ana Jimenez
Rosa Ayala
Daniel Rueda
Beatriz Sanchez-Espiridion
Eulalia Puigdecanet
Blanca Espinet
Lourdes Florensa
Carles Besses
Joaquin Martinez-Lopez
机构：
[1] Hospital Universitario 12 de Octubre,Servicio de Hematología
[2] Servicio de Hematología,Laboratoris de Citologia Hematológica/Citogenética Molecular. Servei de Patologia, GRETNHE
[3] Hospital Virgen de la Salud,Servicio de Hematología
[4] Spanish National Cancer Research Centre (CNIO),undefined
[5] IMIM-Hospital del Mar,undefined
[6] IMIM-Hospital del Mar,undefined
来源：
Annals of Hematology | 2011年 / 90卷
关键词：
Polycythemia vera; Essential thrombocythemia; Gene expression profile; RT-PCR; Response to hydroxyurea; Src family kinase (SFK);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This study investigates the differential gene expression profile of JAK2V617F-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2V617F-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.
引用
收藏
页码：939 / 946
页数：7
相关论文
共 50 条
  • [41] The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype
    Larsen, Thomas Stauffer
    Pallisgaard, Niels
    Moller, Michael Boe
    Hasselbalch, Hans Carl
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (06) : 508 - 515
  • [42] Megakaryocytic Morphology and Clinical Parameters in Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis With and Without JAK2 V617F
    Vytrva, Nataliya
    Stacher, Elvira
    Regitnig, Peter
    Zinke-Cerwenka, Wilma
    Hojas, Sabine
    Hubmann, Eva
    Porwit, Anna
    Bjorkholm, Magnus
    Hoefler, Gerald
    Beham-Schmid, Christine
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2014, 138 (09) : 1203 - 1209
  • [43] Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
    Lee, A-Jin
    Kim, Sang-Gyung
    Nam, Jun Yeb
    Yun, Jaehum
    Ryoo, Hun-Mo
    Bae, Sung Hwa
    BLOOD RESEARCH, 2021, 56 (04) : 259 - 265
  • [44] Mutation of protein kinase JAK2 in polycythemia vera:: new perspectives in physiopathology and therapy
    Marie, I.
    Herve, F.
    REVUE DE MEDECINE INTERNE, 2006, 27 (06): : 473 - 477
  • [45] Major Hematological Response Is the Main Factor for Achieving a Major Molecular Response in JAK2V617F-Positive Essential Thrombocythemia and Polycythemia Vera Patients Treated with Hydroxyurea
    Besses, C.
    Alvarez-Larran, A.
    Martinez-Aviles, L.
    Longaron, R.
    Serrano, S.
    Bellosillo, B.
    BLOOD, 2008, 112 (11) : 246 - 247
  • [46] INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia
    Passamonti, Francesco
    Rumi, Elisa
    Della Porta, Matteo G.
    Portolan, Monica
    Elena, Chiara
    Arcaini, Luca
    Pascutto, Cristiana
    Vanelli, Laura
    Vaddi, Kris
    Lazzarino, Mario
    Cazzola, Mario
    BLOOD, 2009, 114 (22) : 1135 - 1135
  • [47] Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden
    Carobbio, Alessandra
    Finazzi, Guido
    Antonioli, Elisabetta
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    Delaini, Federica
    Rambaldi, Alessandro
    Barbui, Tiziano
    BLOOD, 2008, 112 (11) : 616 - 616
  • [48] GERMLINE HOMOZYGOSITY FOR JAK2 46/1 HAPLOTYPE IS A RISK FACTOR OF DEVELOPING PRIMARY OR POST-POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Andrikovics, H.
    Nahajevszky, S.
    Koszarska, M.
    Meggyesi, N.
    Bors, A.
    Halm, G.
    Lueff, S.
    Lovas, N.
    Matrai, Z.
    Csomor, J.
    Rasonyi, R.
    Egyed, M.
    Varkonyi, J.
    Mikala, G.
    Sipos, A.
    Kozma, A.
    Adam, E.
    Tordai, A.
    Masszi, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 408 - 408
  • [49] JAK2 V617F mutation identifies a biologically distinct subtype of essential thrombocythemia which resembles polycythemia vera.
    Green, A
    Campbell, P
    Scott, L
    Buck, G
    Wheatley, K
    East, C
    Marsden, J
    Duffy, A
    Boyd, E
    Bench, A
    Scott, M
    Vassiliou, G
    Milligan, D
    Smith, S
    Erber, W
    Bareford, D
    Wilkins, B
    Reilly, J
    Harrison, C
    BLOOD, 2005, 106 (11) : 77A - 77A
  • [50] Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients
    Reeves, Brandi N.
    Kim, Soo Jin
    Song, Jihyun
    Wilson, Kathryn J.
    Henderson, Michael W.
    Key, Nigel S.
    Pawlinski, Rafal
    Prchal, Josef T.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (02) : E37 - E40
12345